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The widespread use of antibiotics in association with high-density clinical care has driven the emergence of drug-
resistant bacteria that are adapted to thrive in hospitalized patients. Of particular concern are globally disseminated
methicillin-resistant Staphylococcus aureus (MRSA) clones that cause outbreaks and epidemics associated with health care.
The most rapidly spreading and tenacious health-care-associated clone in Europe currently is EMRSA-15, which was first
detected in the UK in the early 1990s and subsequently spread throughout Europe and beyond. Using phylogenomic
methods to analyze the genome sequences for 193 S. aureus isolates, we were able to show that the current pandemic
population of EMRSA-15 descends from a health-care-associated MRSA epidemic that spread throughout England in the
1980s, which had itself previously emerged from a primarily community-associated methicillin-sensitive population. The
emergence of fluoroquinolone resistance in this EMRSA-15 subclone in the English Midlands during the mid-1980s
appears to have played a key role in triggering pandemic spread, and occurred shortly after the first clinical trials of this
drug. Genome-based coalescence analysis estimated that the population of this subclone over the last 20 yr has grown
four times faster than its progenitor. Using comparative genomic analysis we identified the molecular genetic basis of
99.8% of the antimicrobial resistance phenotypes of the isolates, highlighting the potential of pathogen genome se-
quencing as a diagnostic tool. We document the genetic changes associated with adaptation to the hospital environment
and with increasing drug resistance over time, and how MRSA evolution likely has been influenced by country-specific
drug use regimens.
[Supplemental material is available for this article.]
Methicillin-resistant Staphylococcus aureus (MRSA) remains a ma-
jor global cause of health-care-associated infections since it was
first described five decades ago following the introduction of
penicillinase-stable b-lactam antibiotics into clinical practice
(Klein et al. 2007). During this period, MRSA strains have emerged
several times by acquiring variants of staphylococcal cassette
chromosome mec (SCCmec) elements that carry the mecA methi-
cillin resistance determinant (Robinson and Enright 2003; Nu¨bel
et al. 2008). However, the vast majority of MRSA isolated world-
wide belong to a limited number of clones, some of which are as-
sociated with global epidemics.
Epidemic MRSA-15 (EMRSA-15) has proven to be particularly
successful over the last two decades, transmitting rapidly within
and between hospitals, as well as to different countries. EMRSA-
15 carries a type IV SCCmec element and belongs to multilocus
sequence type ST22. Initially isolated in the southeast of England
in1991 (Richardson andReith 1993), the spread of EMRSA-15 in the
UK health-care setting was rapid; by 2000, EMRSA-15 accounted
for over 60% of MRSA nosocomial bacteremias in England
( Johnson et al. 2001). Over this period the proportion of MRSA
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among S. aureus bacteremia in the UK increased from <2% to 40%
( Johnson et al. 2001).
Shortly after EMRSA-15 was reported in England, MRSA in-
distinguishable from EMRSA-15 were reported to cause outbreaks
in other geographic regions, including Germany, the Czech Re-
public, Portugal, New Zealand, Australia, and Singapore (Pearman
et al. 2001; Witte et al. 2001; Hsu et al. 2005; Melter et al. 2006;
Amorim et al. 2007; Grundmann et al. 2010). These belong to
multilocus sequence type ST22 or its close relatives. In a recent
structured survey, ST22 was the most frequently found MRSA
across Europe (Grundmann et al. 2010), and it was among the
three most frequent MRSA clones in seven out of 15 countries for
which quantitative data were available (Grundmann et al. 2010).
Although reported in many countries, ST22-MRSA accounted
for only 0.2% ofMRSA in a surveillance study recently performed
in the USA (Limbago et al. 2009) and has not, as yet, been re-
ported from South America (Sola et al. 2008) and from large
parts of Asia (Arakere et al. 2005; Ko et al. 2005). ST22-MRSA has
repeatedly demonstrated its ability to supplant and replace other
formerly established MRSA strains (Hsu et al. 2005; Amorim
et al. 2007; Aires-de-Sousa et al. 2008; Witte et al. 2008). Of fur-
ther concern, ST22-MRSA containing the lukS/F genes (encoding
the Panton-Valentine leucocidin) has been reported to cause
community-associated infections (Linde et al. 2005; Witte et al.
2007).
The mechanisms that lead to the emergence and spread of
MRSA strains are of great interest. Despite intense research in this
area, the spatiotemporal dynamics of the population structure and
epidemic spread remain poorly understood, partially due to the
limited resolution provided by contemporary genotyping tools.
In this study we have investigated the origins and evolution of
EMRSA-15 by whole-genome sequencing 193 ST22 isolates from
15 countries, collected between 1990 and 2009. Integrating evo-
lutionary and spatial information, we have reconstructed the spa-
tial and temporal dynamics underpinning the expansion of this
clone and ascertained the genetic changes correlating with its en-
hanced spreading success.
Results
Phylogenomic reconstruction of the ST22 lineage
We determined full-genome sequences from 193 ST22 isolates
(Supplemental Table S1) including isolates both from hospital and
community settings, and also 12 isolates from the earliest de-
scription of EMRSA-15 (Richardson and Reith 1993). Once mobile
genetic elements (MGEs) were excluded, a total of 8095 single
nucleotide polymorphisms (SNPs) in the ‘‘core’’ genomewere used
to reconstruct the evolutionary history of S. aureus ST22 (Fig. 1).
These data revealed that the core genome has accumulated varia-
tion at a rate of 1.33 106 substitutions per nucleotide site per year
(95% Bayesian credible intervals, 1.2 3 106 to 1.4 3 106; Sup-
plemental Table S2). Substitution rates varied slightly among dif-
ferent phylogenetic clades within ST22, but these differences
Figure 1. Phylogeny of ST22 and the emergence of MRSA clones. (A) Maximum likelihood phylogenetic tree of ST22 isolates. The tree was rooted by
using the distantly related S. aureus isolateMSSA476 as an outgroup. Colors indicate the isolates’ countries of origin. Roman numerals indicate acquisitions
of structurally different SCCmec elements, which cause methicillin resistance. (B) Maximum clade credibility tree of the ST22-A clade based on BEAST
analysis using a variable clock rate (uncorrelated lognormal) model. Tips of the tree are constrained by isolation dates, the time scale is shown at the
bottom. Gains and losses (D) of genetic determinants for resistance to methicillin (SCCmec IVh), fluoroquinolones (point mutations in grlA and gyrA),
erythromycin (plasmid-encoded ermC ), and clindamycin (mutations in ermC leader peptide region, c-ermC ) have been mapped on the tree by applying
the parsimony criterion.
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were not significant (Supplemental Table S2). Our rate estimate
was similar to those previously reported for other Staphylococcus
aureus lineages (Lowder et al. 2009; Harris et al. 2010; Nu¨bel
et al. 2010). This estimate then provided a temporal calibration
with which to date the emergence and geographic spread of
EMRSA-15, and evolutionary events that have contributed to its
success.
The level of homoplasy in the SNP data set was extremely
low (homoplasy index, 0.009), reflecting the clonal propagation
of the core genome. The majority of isolates (162 of 193, 84%),
collected from multiple countries, clustered in a single clade
(ST22-A) (Fig. 1A),which encompasses the epidemic strainEMRSA-15.
All but four of the ST22-A isolates carried a single nucleotide de-
letionwithin the ureC gene, resulting in a frame-shift inactivation
of the urease alpha subunit and the consequent nonproduction
of urease (Supplemental Table S1), which is a phenotypic char-
acteristic of EMRSA-15 (Pearman et al. 2001). The four isolates
lacking this deletion are the most basal isolates of the ST22-A
clade (for a list of the genetic variation that distinguishes the
ST22-A clade from the rest of the ST22 population, see Supple-
mental Table S3).
The origin of 173 of the isolates was recorded. Whereas
the vast majority (97%) of ST22-A isolates were collected in
hospitals, this proportion was significantly smaller in non-
ST22 isolates (P < 0.001; Supplemental Table S1). This sug-
gests that members of ST22-A have adapted to transmission
and survival in health-care settings. In contrast, other clades
within ST22 encompass methicillin-susceptible S. aureus iso-
lates, MRSA with different types and subtypes of SCCmec ele-
ments, and isolates with genes for the Panton-Valentine leuco-
cidin toxin. The phylogeny indicates that these isolates have
distinct evolutionary origins from the health-care-associated
clone ST22-A isolates (Supplemental Table S1) and represent the
ST22 founding population from which ST22-A/EMRSA-15 re-
cently emerged.
Included in the sequenced collection are 12 isolates from the
original description of EMRSA-15 (Richardson and Reith 1993).
At the time, Richardson and Reith noted that the majority of
EMRSA-15 in the UK were ciprofloxacin sensitive; however, they
identified a groupof variant isolates from the EnglishWestMidlands
(Birmingham region) that were ciprofloxacin resistant. All eight
ciprofloxacin-sensitive EMRSA-15 isolates from the Richardson
and Reith study are found in the ST22-A1 clade (Fig. 1B; Supple-
mental Table S1), whereas the four ciprofloxacin-resistant isolates
form a basal group in clade ST22-A2. It therefore appears that ST22-
A1, while spreading among hospitals in the British Isles, formed
a progenitor population from which a fluoroquinolone-resistant
pandemic clone (i.e., ST22-A2) emerged.
EMRSA-15 genotype
A combination of gene acquisition and core genome muta-
tion shapes the genome of ST22. Therefore, in addition to SNP
discovery based on mapping sequencing reads to a reference
genome, we also determined the full genetic repertoire from
each of the isolates, including MGEs, by de novo assemblies of
sequencing reads. Using the phylogenetic reconstruction, we
have been able to examine the evolution of ST22-A, and also
pinpoint the genetic events that accompanied the emergence of
EMRSA-15.
A significant component of the S. aureus genome is derived
from MGEs that contribute to the accessory genome and includes
SCCmec, prophages, S. aureus Pathogenicity Islands (SaPI), IS ele-
ments, transposons, and plasmids (Lindsay and Holden 2004).
Comparative analysis reveals the composition and fluidity of the
ST22 accessory genome (Fig. 2), and this accounts for between 4%
and 14% of CDS within the ST22 genomes. Comparison of the
ST22-A and non-ST22-A strains reveals that, typically, the accessory
genomeof ST22-A strains is larger and less variable than that of non-
ST22-A strains (Fig. 2A).
Analysis of the origins and location of CDSs in the ST22 acces-
sory genomes show MGEs belonging to a range of classes (Fig. 2B),
with prophages being the largest component. The accessory ge-
nome variation within the ST22-A isolates results from both the
loss of ancestrally acquired elements such as prophages and SCCmec
(Fig. 2) and the gain on multiple occasions of plasmids and pro-
phages (Supplemental Table S1).
The ST22 reference genome, HO 5096 0412, is a representa-
tive of EMRSA-15 and is found in the ST22-A2 clade (Supple-
mental Table S1). Among the MGEs it contains are the following:
an SCCmec IVh element (Milheirico et al. 2007), which carries the
mecA gene encodingmethicillin resistance; a Tn554 like-transposon,
encoding a b-lactamase; two prophages (fSa2HO 5096 0412, which
encodes a BcgI-like restriction enzyme, and fSa3HO 5096 0412,
which encodes staphylokinase [Sako and Tsuchida 1983]) and
the immune evasion proteins CHIPS and SCIN (van Wamel et al.
2006); and a 2.4-kb ermC carrying plasmid (Ko¨ser et al. 2012).
Comparative genomic analysis of the ST22 isolates showed that
these elements were conserved in the ST22-A population, with
few exceptions (Supplemental Table S1).
Using the phylogeny we showed that the SCCmec IVh ele-
ment was acquired once, just prior to the emergence of ST22-A.
Similarly, fSa2 appears to have been acquired prior to the
emergence of ST22-A (Supplemental Table S3). Prophage fSa3
seems to have been acquired before the emergence of the ST22-A
lineage because it is present in members of the non-ST22-A
population. A SaPI element encoding enterotoxin C (Novick
2003) is absent from the reference genome, but present in;68%
of the ST22-A isolates (Supplemental Table S1). This element is
also found in non-ST22-A isolates at the same site (39 region of
GMP synthase, SAEMRSA1503430), suggesting that like fSa3,
its association with the ST22 lineage predates the emergence
of ST22-A. In addition, other MGEs are variably present in the
pandemic clone, several of which are associated with the
transfer of antibiotic resistance genes; but, unlike the elements
above, none of these have been stably maintained since ST22-A2
emerged.
In addition to the MGE-induced changes in the genomic
architecture of ST22-A, all ST22-A genomes possess five indels in
the core genome, including a 2268-bp deletion in the fibronectin-
binding protein (FnBP) locus (Supplemental Table S3). This FnBP
deletion was caused by homologous recombination between the
C-terminal region of fnbA and the N-terminal region of fnbB,
resulting in a gene fusion, fnbA–fnbB. FnBPA and FnBPB bind the
host extracellular-matrix proteins fibronectin, fibrinogen, and
elastin (Greene et al. 1995; Roche et al. 2004), allowing the
S. aureus to connect to cellular integrins and trigger internaliza-
tion (Fowler et al. 2000). In the ST22 isolates containing fnbA and
fnbB (non-ST22-A), these two homologs are ;71% identical
(;67% identical at the amino acid level) and 2871 bp and 3045 bp
in length. The predicted recombination site occurs;1850 bp into
fnbA, thereby generating a gene fusion that retains most of the
sequence of fnbA. The fusion protein is the same length as FnBPA
and is 98.5% identical, whereas it is only 68.6% identical to
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FnBPB. It is therefore likely that the encoded fusion protein
retains most of the binding properties of FnBPA (Roche et al.
2004).
From the phylogeny we defined the genetic changes that
differentiate the ST22-A2 and ST22-A1 populations (Supplemental
Table S4). That differentiation was not marked by any unique
acquisitions of MGEs. Instead, the variation in the core genome
that marks this split includes a single insertion and 30 SNPs, of
which 18 result in nonsynonymous substitutions, and one non-
sense mutation. The nonsense mutation introduces a premature
stop codon in the ECM-binding protein homolog Ebh. This very
large surface protein binds fibronectin and contains a C-terminal
transmembrane domain that anchors the intact protein in the
cell envelope (Clarke et al. 2002). The truncated variant caused
by the nonsense mutation lacks this transmembrane domain,
and ST22-A2 isolates likely do not express this adhesin on their
surface.
Demography and phylogeography
The high proportion of ST22-A isolates in the sample and their
very low sequence diversity, points to ST22-A being a highly fit,
recently emerged MRSA strain. This inference is further sup-
ported by coalescence analyses estimating that the popula-
tion size of ST22-A has grown exponentially by 24% each year
(Bayesian credibility intervals, 20%–29%) since the 1990s, which
is four times faster than the average growth of other ST22 strains
(non-ST22-A) (Fig. 3). The rapid population expansion is accom-
panied by the star-shaped branching pattern of the ST22-A clade
(Fig. 1A).
A Bayesian phylogeographic reconstruction of ancestral
nodes in the phylogenetic tree supports a root of the ST22-A clade
in the UK. Within a few years of its emergence there, multiple ex-
ports spread it from the UK to Australia as well as to various coun-
tries in Europe, Asia, and Africa (Fig. 1B; Supplemental Fig. S1).
Figure 2. Accessory genome diversity in ST22. CDSs in the accessory genome of each isolate were clustered and assigned to homology groups (HGs).
(A) Conservation of accessory genome HGs across the ST22 population. The isolates are ordered according to the phylogeny displayed along the left and
top of the figure. The conservedHGs in the pairwise comparison are displayed as a heatmapmatrix and colored according to the number of conserved HGs
(range 64 to 235HGs) per pair; see figure for scale. (B) Size and composition of each isolate’s accessory genome based on the number of HGCDSs. TheHGs
have been subdivided into different mobile genetic element types based on matches to an annotated MGE reference set included in the clustering (see
legend to figure).
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Early ST22-A isolates (clade ST22-A1 in Fig. 1B) were susceptible to
fluoroquinolones, and apparently did not spread beyond the
British Isles. Bayesian modeling of the spread of fluoroquinolone-
resistant ST22-A2 in the UK suggests that ST22-A2 originated
within the English Midlands (Fig. 4), and was restricted to this
geographical region until the late 1980s. The same analysis further
suggests that isolates from the Midlands seeded infection to the
north, reaching Scotland by around 1993, but also to the south,
reaching London around 1998 (Fig. 4; SupplementalMovie S1). By
2000, the epidemic had spread to most locations within the UK
via multiple routes and sources (e.g., Bristol, from the Southern
England and Midlands; Manchester, from the Midlands and the
North; Aberdeen from elsewhere in Scotland andNorth England).
The UK epidemic then spread globally through multiple inter-
national transmission events (Fig. 1).
Estimates for the timings of first appearances of ST22-A in
countries beyond the UK (Supplemental Fig. S1) are concordant
with available epidemiological evidence for EMRSA-15, suggesting
epidemic expansion in those countries soon after its introduction
(Richardson and Reith 1993; Pearman et al. 2001;Witte et al. 2001;
Hsu et al. 2005; Melter et al. 2006). Our data reveal multiple intro-
ductions from the UK into Germany, Denmark, and Australia, pos-
sibly via the migration of colonized health-care workers (Pearman
et al. 2001). Country-specific clades in the phylogenetic tree point
to subsequent diversification within many recipient countries,
and the data support additional spreading events, e.g., from
Portugal to Germany (Fig. 1B). Because basal isolates outside the
ST22-A clade are also geographically widespread, ST22 was almost
certainly present in many countries prior to the emergence of
ST22-A (Fig. 1A; Supplemental Table S1). Indeed, methicillin-
susceptible ST22 is known to form a common component of the
nasal carriage population inmany places (Feil et al. 2003; Holtfreter
et al. 2007; Ruimy et al. 2009).
The development of drug resistance in ST22
The broad range of resistance traits within ST22-A contrasts strik-
ingly with the more susceptible and diverse population from
which it emerged (Supplemental Table S1). For ST22-A, the number
of resistance traits per isolate increasedwith time (P < 0.001) (Fig. 5),
whereas the trend in the rest of the population (non-ST22-A) was
not statistically significant (P > 0.1).
In order to investigate the evolutionary events responsible
for the increase in resistance, we analyzed the whole-genome se-
quences to elucidate the antibiotic resistance genotype of ST22.
Molecular determinants within the genomes explained 99.8% of
the measured phenotypic resistance traits (847 resistance traits in
total). Only two phenotypes did not correlate with the predicted
genotypes. HO 7258 0475 05 was erythromycin resistant, but
lacked ermC and all other erythromycin resistance mechanisms
that have been documented in the literature. Strain 09-00678 con-
tained thyA and dfrA, but was not phenotypically cotrimoxazole
resistant. For both isolates it is possible that the drug-resistance
determinants were lost during lab culturing prior to DNA prepara-
tion or phenotypic testing.
Our genomic analyses showed that evolution of resistance in
ST22 has occurred in a stepwise fashion encompassing both the
core and accessory genomes. Acquisition of a transposon-encoded
b-lactamase BlaZ confers penicillin resistance, and the widespread
Figure 3. Exponential growth rates (l) of ST22-A and other ST22
isolates (posterior probability density functions from Bayesian analy-
sis). ST22-A is estimated to have grown significantly faster than
non-ST22-A. The population size N at time t was modeled by N(t) =
N(0)3e(l3 t), where l is the exponential growth rate and t is measured
in years. Accordingly, the population size change per year is el.
Figure 4. Bayesian reconstruction of the spread of ST22-A2 in the UK. A
continuous spatial diffusion model was used to reconstruct the finer-scale
geographical dispersal of ST22-A2 within the UK and to predict the origin
of fluoroquinolone resistance. Lines indicate the inferred routes of spread
with confidence displayed as green ovals representing 80% of the highest
posterior density (HPD) for latitude and longitude. The timing of trans-
mission events are represented by red (old) to black (recent) lines and
light- to dark-green oval shading (for the animation of the reconstruction
of the spread, see Supplemental File S2). The maps are based on satellite
pictures made available at Google Earth (http://earth.google.com).
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distribution of this transposon in ST22 is consistent with a single,
primordial development of b-lactam resistance, and probably
reflects usage of penicillin since the 1940s.Only six ST22 isolates in
our collection are sensitive to penicillin, four of which have lost
the Tn552-like transposon carrying the blaZ gene, and one of which
carries a blaZ gene inactivated through an IS element insertion in its
promoter region (Supplemental Table S1). The penicillin-resistant
ST22 population then gave rise to several methicillin-resistant
clones, which emerged through imports of SCCmec elements into
their chromosomes. The phylogenomic distribution of different
SCCmec variants in the phylogenomic context provides evidence
of at least seven independent imports into ST22, one replacement
of SCCmec type IV by SCCmec type V, and two secondary losses of
SCCmec through precise excision by homologous recombination
between flanking direct repeat sequences (Fig. 1; Supplemental
Table S1). As described above, ST22-A emerged after the acquisition
of SCCmec IVh, which is predicted to have occurred over a decade
before the first report of EMRSA-15 (Fig. 1; Richardson and Reith
1993).
Around 1986 (95% Bayesian credible intervals 1984–1988)
ST22-A developed fluoroquinolone resistance through two point
mutations generating amino acid substitutions Ser80Phe in topo-
isomerase IV (GrlA) and Ser84Leu in gyrase A (GyrA). This geno-
type is found in the ST22-A2 clade (Fig. 1B) that spread throughout
the UK and globally. We note that our dating estimate for acqui-
sition of fluoroquinolone resistance coincides closely with the in-
troduction of fluoroquinolone drugs into clinical medicine in the
UK, ciprofloxacin being first licensed in February 1987. Further,
phylogeographic modeling suggested that fluoroquinolone resis-
tance emerged in the English Midlands in the early 1990s (Fig. 4).
Notably, clinical studies with ciprofloxacin occurred in the Mid-
lands prior to the licensing of ciprofloxacin in 1987 (Crump et al.
1983; Finch et al. 1986; Silverman et al. 1986).
In the subsequent decades the pandemic has continued along
a trajectory of increasing antibiotic resistance, developing re-
sistance to a range of antibiotics of different classes (tetracy-
clines, aminoglycosides, cotrimoxazole, fusidic acid, mupirocin,
and oxazolidinones) on multiple occasions (Supplemental Fig. S2;
Supplemental Table S1). The development of these resistances has
been rather sporadic and also less stably maintained than those
against b-lactams and fluoroquinolones, but nevertheless dem-
onstrates clear evidence of the strong selective pressure exerted
by antibiotic usage and clinical practice. For example, our data
set documents multiple independent events of erythromycin-
resistance acquisition based on the uptake of plasmids encoding
the ErmC erythromycin ribosomal methylase (Fig. 1B). Phyloge-
netic analysis also indicates that the ermC plasmid was lost mul-
tiple times, and in several cases these losses affect entire clades,
suggesting that they represent genuine events in the natural pop-
ulation rather than laboratory artefacts (Fig. 1B). ErmC addition-
ally confers resistance to clindamycin when mutations in the
leader peptide region of the ermC gene cause its constitutive ex-
pression (Levin et al. 2005). All clindamycin-resistant isolates
possess genetic rearrangements that disrupt the promoter region
upstream of ermC, including deletions of part or all of the ermC
leader peptide region or insertion of an IS element in ermC leader
peptide region. At least eight independent, structurally different,
mutations have generated clindamycin resistance in the pop-
ulation examined (Supplemental Table S1) and five of these were
found in ST22-A (denoted ‘‘c-ermC’’ in Fig. 1B). The data also sug-
gest that country-specific variation in antibiotic usage may be
shaping the geographic distribution of resistance. The prescription
level of clindamycin is much higher in Germany than in the UK
(Coenen et al. 2006;Meyer et al. 2006; deWith et al. 2011), causing
selective pressure for a high prevalence of clindamycin resistance.
Among the 34 erythromycin-resistant isolates from Germany, 32
(94%) are also clindamycin resistant, whereas none of the 45 UK
isolates are resistant to clindamycin (significant difference, P <
0.001, Fisher’s exact test).
Discussion
EMRSA-15 represents a ‘‘measurably evolving population’’
(Drummond et al. 2003), accumulating genetic variation over ep-
idemiological timescales at an average rate similar to previous es-
timates for other S. aureus strains (Lowder et al. 2009; Harris et al.
2010; Nu¨bel et al. 2010). One consequence of this fast nucleotide
substitution rate is that evolutionary events could be dated, in-
cluding the stepwise acquisition, refinement, and loss of multiple
drug-resistance traits. Furthermore, past temporal changes in pop-
ulation size and geographic expansion could be analyzed retro-
spectively based on themolecular traces that these processes left in
the genomes. These conclusionswere possible because our genome
sequences span a wide range of time and space, which is a pre-
requisite for such coalescence-based analyses. Our data revealed
much more detail about the pathogen’s population history than
would have been possible with a snapshot survey from a single
time point.
In principle, changes in the frequency of a genetic variant
may be due to stochastic events or genetic adaptation and selection
(Keim and Wagner 2009). For the highly successful MRSA strains
described here, it seems plausible that they are more specialized to
the restricted ecological niches in the hospital environment, where
exposure to antibiotics is common and survival depends on effi-
cient transmission between patients in close contact, than is the
ancestral population from which they emerged. This scenario is
supported by the observation that hospital-associatedMRSA rarely
establish themselves in the community. Aside from the devel-
opment of antibiotic resistance, little is known about other adap-
tive genetic changes that promote the success of S. aureus (Gomes
et al. 2005; Chambers and Deleo 2009). A recent microarray-based
investigation did not reveal any concordant differences between
Figure 5. Increase in antibiotic resistance traits within ST22-A pop-
ulation over time. Number of genotypic resistance determinants per
ST22-A isolate (red, no. 162) and non-ST22-A isolates (blue, no. 31) from
all countries, 1990–2008, including regression lines with 95% confidence
interval for each group. Size of circle corresponds to number of isolates.
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gene contents of highly successful (‘‘epidemic’’) versus sporadic
S. aureus strains (Kuhn et al. 2010). Recently, a phage-encoded
virulence determinant (which is not present in ST22) has been
shown to be associated with enhanced spreading of MRSA in Asia
(Li et al. 2012). Phenotypic changes may be caused by genetic
changes that are subtler than the gain of entire genes through
horizontal gene transfer, or their loss (Kennedy et al. 2008; Olsen
et al. 2010). However, our analysis of the genetic changes that ac-
companied the emergence of EMRSA-15 failed to pinpoint a single
determinant, but, in contrast, identified a series of gene acquisition
events and mutations that potentially promote the success of this
clone in the hospital setting (Supplemental Tables S3, S4). Prom-
inent among these are those associated with antibiotic resistance.
Evidence of the selective pressure exerted by the widespread
use of broad-spectrum antibiotics in hospitals and beyond is man-
ifest in the ST22 isolates’ genomes. In order to unravel the evo-
lutionary events surrounding the development of resistance, we
examined the genotypic basis of the antibiotic resistance pheno-
types. These analyses permit an evaluation of the utility of genome
sequencing as a diagnostic tool for the prediction of antibiotic
resistance. Our in silico analysis of genome sequences identified
the molecular correlates for >99% of the phenotypic antimicrobial
resistance traits. This strong correlation documents the impressive
success of past research into resistance against established antibi-
otics, leaving few undiscovered resistance mechanisms in MRSA.
Of note, several mutations in the ermC promoter region were
structurally related, but not identical to previously reported mu-
tations (Levin et al. 2005), and oxazilidinone resistance in our
isolate collection was due to a mechanism that had been recently
described from in vitro experiments (Locke et al. 2009), but had
not previously been reported from clinical isolates ( Jones et al.
2009). These observations highlight the potential of large-scale
sequence analyses for discovering novel mechanisms. While vari-
ous molecular methods were used in the past to detect resistance
determinants in clinical isolates (Bergeron and Ouellette 1998),
whole-genome sequences enabled a screen for all known genes
and mutations in a single experiment. For the 12 antibiotics, we
screened for 116 different alleles that were known to confer anti-
biotic resistance by searching antibiotic resistance genes in the de
novo assemblies or SNPs in the core genome (Supplemental Table
S5). Accordingly, we were able to demonstrate that it should be
possible to predict with high accuracy the full resistance profile
from the sequence data alone. Such predictions may be more
challenging for other organisms whose mechanisms of resistances
are poorly studied, or more complex, such as those associated with
efflux and permeability.
The reduction in costs and time to generate genomic se-
quences has recently led to genome sequencing being developed as
a clinical diagnostic tool that can be used to investigate and stop
outbreaks in hospitals (Eyre et al. 2012; Harris et al. 2012; Ko¨ser
et al. 2012; Snitkin et al. 2012). The observations from this study
herald an important development in the progress of transitioning
whole-genome sequencing from a research tool to a diagnostic
application. Whole-genome sequencing can provide both high
discriminatory power formolecular epidemiology and a prediction
of antibiotic resistance, which is valuable for ‘‘near real-time’’ in-
fection control and clinicalmanagement, and also for surveillance,
horizon scanning of the clinical population for the evolution of
drug resistance, and the identification of emerging threats.
With the benefit of hindsight it is clear that the emergence of
the ST22-A2 variant of the EMRSA-15 population in the UK in the
1980s marked one such threat. Originating in the English Mid-
lands, it spread rapidly during the 1990s, becoming endemic in
UK hospitals, andwas associatedwith an upsurge in the number of
MRSA infections ( Johnson et al. 2001).
Of the genetic events that define the emergence of ST22-A2,
the two nonsynonymous SNPs associated with fluoroquinolone
resistance would appear to be good candidates to explain the suc-
cess of the clone. Fluoroquinolones are readily excreted in sweat
and can suppress the growth of the normal microbiota, which
includes S. aureus that colonizes skin, nose, and throat (Hawkey
1997). Fluoroquinolone resistant ST22-A2, therefore, may have
a competitive edge, promoting colonization and survival in the
hospital environment where this class of antibiotic is frequently
used. Indeed, widespread fluoroquinolone usage has previously
been reported to promote the spread of fluoroquinolone-resistant
MRSA, even though this class of antibiotics is not normally used to
treat S. aureus infections (Weber et al. 2003; Salangsang et al. 2010).
A recent study examining MRSA rates in a tertiary hospital over
a 10-yr period identified a significant increase in MRSA infection
rates after an increase in fluoroquinolone prescription levels fol-
lowing a period of restricted usage (Parienti et al. 2011). Conversely,
significant falls in MRSA rates have been linked to a decrease in
the usage of fluoroquinolones over a 4-yr period (Lafaurie et al.
2012). In a prevalence study looking at elderly patients admitted
to hospitals in the UK, a strong association was found between
MRSA colonization and prior ciprofloxacin exposure (Hori et al.
2002), with EMRSA-15 being the dominant lineage detected in
this study (75.9% of MRSA isolates).
The biological and ecological advantage of fluoroquinolone
resistance would therefore appear to be clear. However, to under-
stand the remarkable success of ST22-A2 requires insights into the
historic clinical context in which it emerged. Our analysis suggests
that development of fluoroquinolone resistance coincided closely
with the introduction of fluoroquinolone drugs into routine clin-
ical medicine in 1987. Initially, ST22-A2 isolates were restricted to
the English Midlands until 1990, after which point the clone
spread rapidly. During this time the use of fluoroquinolones in the
hospital and community settings increased rapidly, doubling from
1990 to 1993 (Livermore et al. 2002). Throughout the rest of the
1990s, usage in the community stabilized, but the usage in hos-
pitals continued to grow steadily both in absolute terms and also as
a proportion of all antibiotic usage, constituting 31.5% of total
usage in 1999 compared with 18.9% in 1992 (Livermore et al.
2002). The emergence and rapid spread of ST22-A2 in theUK in the
1990s, therefore, perhaps reflects changes in clinical prescription
regimens. In this regard it is worth noting that we also uncovered
evidence of the recent influence that country-specific antibiotic
regimens (clindamycin usage in Germany vs. the UK) have had in
shaping the MRSA population within Europe, illustrating the link
between pathogen population structure and national antibiotic
prescription policymaking.
The pandemic success of EMRSA-15 cannot, however, be sim-
ply characterized as a case of the right mutation at the right time.
Fluoroquinolone resistance is not unique to ST22-A2, but is also
found amongnon-ST22-A isolates in the collection as the result of
homoplasic substitutions (Supplemental Table S1), as well as in
other epidemic MRSA clones (Fluit et al. 2001; Woodford and
Livermore 2009; Tenover et al. 2011). Hence, other facets of the
ST22-A2 must have contributed to its outstanding success. Fluo-
roquinolone resistant ST22-A2 emerged from a hospital-adapted
genetic background (ST22-A1) (Fig. 1) that was already successful,
and spread through English hospitals by the start of the 1990s
(Richardson and Reith 1993).
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An important class of S. aureus proteins involved in host
colonization are surface-expressed binding proteins (Edwards et al.
2012). Analysis of the genetic events that define the emergence of
ST22-A identified mutations in two surface-expressed binding
proteins, FnBP and Ehb, both of which bind fibronectin, a glyco-
protein component of the host’s extracellular matrix. Ebh is one of
the largest bacterial proteins (;1.1 MDa) (Clarke et al. 2002). The
pandemic clone of EMRSA-15 has a nonsense mutation that ab-
lates expression of Ehb at the cell envelope. Previous studies dem-
onstrated that mutation of ebh had no effect on the growth rate or
pathogenicity in a murine skin abscess model of infection (Clarke
et al. 2002). Notably, this protein is intact in some successful
MRSA lineages (Gill et al. 2005; Diep et al. 2006; Holden et al.
2010) and mutated in others (Kuroda et al. 2001; Holden et al.
2004). Therefore, it is unlikely that mutation of Ehb is the sole
determinant of increased transmissibility of ST22-A. Its effect may
be more pronounced due to other mutations, for example, the
deletion in the fibronectin-binding protein locus.
Recombination between the C-terminal regions of fnbA and
fnbB results in an fnbA–fnbB gene fusion and an effective reduction
in fnb gene copy number at this locus due to the deletion of fnbB.
Studies with clinical isolates suggested that strains associated with
invasive disease are significantly more likely to have two fnb genes
(Peacock et al. 2000). Molecular studies have also shown that both
FnBPA and FnBPB are required for the establishment of septic in-
fection (Shinji et al. 2011). However, in S. aureus that have both
homologs, deletion of either gene does not abolish fibronectin-
binding capacity of the cell (Greene et al. 1995). The functional
consequences of the deletion and resulting gene fusion on the
host–cell interaction and transmissibility are unclear, especially
when considering that there is also a mutation in ebh.
Interestingly, althoughmost other representatives of the main
MRSA lineages contain two copies of the fnb genes (Kuroda et al.
2001; Gill et al. 2005; Diep et al. 2006; Holden et al. 2010), EMRSA-
16, an unrelated epidemic MRSA lineage that originated in the
UK around the same time as EMRSA-15, also contains a deletion-
mediated fibronectin-binding protein gene fusion (Holden et al.
2004). Like EMRSA-15, EMRSA-16 also has evolved fluoroquinolone
resistance via gyrA and grlA mutations just prior to its emergence
(McAdam et al. 2012). Both of these epidemic clones spread
throughout UK hospitals since the 1990s ( Johnson et al. 2001), al-
beit EMRSA-15 has been the more successful of the two clones
(Ellington et al. 2010). It is therefore intriguing that they share
the fluoroquinolone resistance and fnbA–fnbB genotypes that
affect resistance and host cell interaction. However, pinpointing
the genetic basis of their success is more complex. In the EMRSA-
16 background, mutations in the accessory gene regulator C
and a-hemolysin (DeLeo et al. 2011) and squalene desaturase
(McAdam et al. 2012) have been identified and hypothesized to
contribute to its epidemic success. However, these are not found
in EMRSA-15. In order to fully elucidate the genetic basis for the
relative success of EMRSA-15, extensive experiments investigat-
ing the colonization and transmission properties of the hospital-
adapted clone are required.
Methods
Bacterial isolates
Sources and properties of 193 S. aureus isolates are listed in Sup-
plemental Table S1. In assembling the collection in this study, we
included isolates that encompass wide geographical and temporal
ranges, but also included isolates that reflect the documented
history and prevalence of EMRSA-15 and ST22.
Susceptibility to antibiotics was tested by using the stan-
dardized broth microdilution method according to DIN58940
instructions (Deutsches Institut fuer Normung 2007), and phe-
notypic resistance was defined by applying minimum inhibitory
concentration breakpoints from the European Committee on An-
timicrobial Susceptibility Testing (EUCAST; http://www.eucast.
org/). In total, 18 antibiotics were tested (penicillin, PEN; oxacil-
lin, OXA; gentamycin, GEN; linezolid, LNZ; erythromycin, ERY;
clindamycin, CLI; ciprofloxacin, CIP; fusidic acid, FUS; mupirocin,
MUP; moxifloxacin, MFL; co-trimoxazole, SXT; tetracyline, TET;
vancomycin, VAN; teicoplanin,TPL; rifampicin, RAM; phospho-
mycin, PHO; tigecycline, TGC; daptomycin, DAP), of which 12 had
resistance in at least one isolate in the collection (Supplemental
Table S1). Bacterial typing was performed as described previously
(Strommenger et al. 2008).
Genomic library creation and multiplex sequencing
Unique index-tagged libraries for each samplewere created, and up
to 12 separate libraries were sequenced in each of eight channels
in Illumina Genome Analyzer GAII cells with 54-base paired-end
reads of Illumina HiSeq with 75-base paired-end reads. The index-
tag sequence information was used for downstream processing to
assign reads to the individual samples.
Detection of SNPs in the core genome
The paired-end reads were mapped against the chromosome of
S. aureus HO 5096 0412 (accession no. HE681097) (Ko¨ser et al.
2012), a representative of EMRSA-15 that was isolated from a fatal
neonatal infection in Suffolk, UK in February 2005. SNPs were
identified as described in Croucher et al. (2011). Indels were
identified using Dindel (Albers et al. 2011). Unmapped reads and
sequences that were not present in all genomes were not con-
sidered as part of the core genome, and therefore SNPs from these
regions were not included in the analysis. SNPs falling within
MGEs regions were also excluded from the core genome, as well as
those falling in high-density SNP regions, which could have arisen
by recombination. The core genome was curated manually to en-
sure a high-quality data set for subsequent phylogenetic analysis
and comprised of 2,643,131 bp.
Phylogenetic analysis
A phylogeny was drawn for ST22 using RAxML v0.7.4 (Stamatakis
et al. 2005) to estimate the trees for all SNPs called from the core
genome. The general time-reversible model with gamma correc-
tion was used for among-site rate variation for 10 initial trees.
Comparative analysis
Raw Illumina data were split to generate paired-end reads and
assembled using a de novo genome assembly program, Velvet
v0.7.03 (Zerbino and Birney 2008), to generate a multicontig draft
genome for each of 193 S. aureus isolates. Gene prediction was
performed using Prodigal (Hyatt et al. 2010). Predicted CDSs were
compared using BLASTP (Ausubel et al. 1995), and the proteins
were clustered into homology groups using TribeMCL (Center for
Mathematics and Computer Science and EMBL-EBI) (Enright et al.
2002) with a cut-off of 1e50.
Included in the clustering data set were the complete genome
sequences of S. aureus available in the public sequence databases.
MGEs in these sequences were identified using comparative
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genomic analysis and manual curation. Homology groups (HG)
were categorized according to their origins based on matches to
CDSs from the MGE reference set that clustered within the group.
For the purpose of the preliminary accessory genome analysis, HG
origins were subdivided into Prophage, Conjugative transposon,
Plasmid, S. aureus Pathogenicity Island (SaPI), SCCmec element,
Transposon, Hypothetical proteins, and others. Conjugative
transposon/Plasmid reference sequences included Tn916-like
(Clewell et al. 1985) and Tn5801-like elements (Kuroda et al. 2001)
as well as integrated conjugative elements such as ICE6013 (Smyth
and Robinson 2009), whereas Transposon included Tn554 (Phillips
and Novick 1979), Tn552 (Rowland and Dyke 1989), and IS ele-
ments. Hypothetical protein HGs did not have any matches with
either core or MGE CDSs from the reference set. HGs defined as
‘‘Other’’ indicate that there were no matches with MGE CDSs, but
there were matches with CDSs from the core regions of the ref-
erence genomes. In some cases, there were examples of clustered
proteins from more than one origin being present in the single
HG; for example, Prophage and SaPI and Conjugative trans-
posons and Plasmid. This reflects the shared evolutionary origins
and mechanisms of transfer MGEs. In these cases, HGs were as-
signed arbitrarily.
Detailed comparisons of genome sequences were conducted
on the de novo assemblies using BLASTN (Ausubel et al. 1995),
and were facilitated by using the Artemis Comparison Tool (ACT)
(Carver et al. 2005).
Determination of antibiotic resistance genotype
The literature was extensively mined for the genetic basis of anti-
biotic resistance in S. aureus. A database was compiled that con-
tained horizontally acquired genes and core gene mutations that
conferred antibiotic resistance. Antibiotic resistance conferred by
SNPs in components of the core chromosome were identified by
manual curation; substitutions were compared with antibiotic re-
sistance mutations in S. aureus proteins detailed in the literature.
The presence of antibiotic resistance genes of MGEs was inves-
tigated using BLASTN (Altschul et al. 1990) to compare de novo
assemblies against a database of S. aureus resistance genes compiled
from literature and public sequence database searches, and also by
mapping sequence reads to a pseudo-molecule consisting of con-
catenated antibiotic resistance genes as detailed by Ko¨ser et al.
(2012).
The genotype of each isolate was searched for the resistance
genes and/or mutations for the antibiotics tested; for the 12 anti-
biotics for which resistance was detected, 847 incidences in total,
116 different genes or alleles were searched for. The presence of
the following known resistance genes and mutations/deletions of
determinants conferring resistance were identified: mecA (Utsui
and Yokota 1985), ermC (Catchpole et al. 1988), blaZ (Voladri and
Kernodle 1998), tetK (Khan and Novick 1983), fusC (O’Neill et al.
2007), fusA (mutation) (Chen et al. 2010), dfrA (Rouch et al. 1989),
thyA (deletion) (Leelaporn et al. 1994), ileS-2 (Hodgson et al. 1994),
aacA-aphD (Rouch et al. 1987), grlA (mutation) (Griggs et al. 2003),
gyrA (mutation) (Griggs et al. 2003), rplC (mutation) (Locke et al.
2009), and ermC plasmid (deletion) (Weisblum 1995) (see Supple-
mental Table S1).
Assessing the association of the number of genetic determinants
of resistance with time
The total number of resistance genes and mutations/deletions
conferring resistance were summed for each strain. Linear re-
gressionwas used to assess the association of the number of genetic
determinants of resistance per strain with time. The dependent
variable was the number of genetic determinants of resistance per
strain, and the independent variable was time (year of isolation).
Significance was assessed at P < 0.05. This analysis was applied to
all 162 ST22-A isolates, from all countries, and separately to the
77 ST22-A isolates from the UK. This latter analysis was performed
to evaluate the association of time with the number of genetic
resistance determinants in a single country. Linear regression with
the non-ST22-A strains demonstrated that the number of genetic
determinants of resistance per strain was not significantly associ-
ated with time (P > 0.10).
Assessing the association of ST22-A strains with hospital origin
Out of the 162 global ST22-A strains, there were 147 where it was
known whether or not they were hospital associated: 142 (96%)
were hospital associated, and five were not. Of the 31 non-ST22-A
strains, there were 26 where it was known whether or not they
were hospital associated: 13 (50%) were hospital associated, and
13 were not. These proportions were significantly different ac-
cording to Fisher’s exact test (P < 0.05).
Bayesian analyses
Weused the Bayesian softwarepackage, BEAST (v1.7.1) (Drummond
et al. 2012) to investigate the temporal, spatial, and demographic
evolution of ST22. The core genome was retained for the analyses
after discarding all ambiguous bases and strains that showed ad-
mixture, resulting in a final alignment of 193 taxa and 2,154,246
bp. The different clades of ST22 (A and non-A) have different de-
mographic histories, as inferred from the shape of their coalescent
trees. Non-ST22-A individuals coalesce further back in time and at
a slower rate than ST22-A individuals, and the latter have a more
star-like genealogy. For this reason, we analyzed these two clades
separately (25 taxa for non-ST22-A and 162 taxa for ST22-A). We
used an uncorrelated lognormal distribution (variable clock rate) to
model the rate of evolution and constrained the tips of the phy-
logeny to their dates of isolation to calibrate that rate, as well as
giving it a default uniform prior of between 0 and 1. We used the
HKY85 model of nucleotide substitution (Hasegawa et al. 1985)
with four discrete gamma-distributed rate categories, and tomodel
the relative node ages, ran the two data sets under both the con-
stant size and exponential size coalescent tree prior. All other de-
fault parameters in the programBEAUti v1.6.2were used. Tomodel
the global geographical spread, we calculated the probabilities of
transfer between each discrete location (i.e., country) via a con-
tinuous-timeMarkov chain with a nonreversible infinitesimal rate
matrix, using this to find the location at ancestral nodes (Lemey
et al. 2009; Edwards et al. 2011). To reduce the number of param-
eters to estimate, we utilized Bayesian stochastic search variable
selection (BSSVS), where at any point in the Monte Carlo Markov
chain (MCMC) the transition probabilities of some states can be
set to zero, with the prior designed to minimize the number of
location changes as described in Lemey et al. (2009). To infer the
geographic spread within the UK and to predict the root state of
the fluoroquinolone-resistant isolates, we modeled diffusion over
a continuous two-dimensional space assuming a Brownianmotion
(or Weiner process), with the rate of diffusion assumed to be con-
stant over the entire tree and estimated from the data (Lemey et al.
2010). For this analysis, we used ST22-A strains and discarded
strains that were fluoroquinolone-sensitive and those that did not
have exact latitude and longitude information, leaving a total of
60 taxa. The uncertainty in root location is represented as 80% of
the highest posterior density of the continuous traits: latitude and
longitude. We calculated a posterior distribution of all parameters
using two separateMCMCs and terminated the runs after checking
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for efficient mixing, convergence, and checking that 90% of the
distribution was post ‘‘burn-in.’’ To estimate the timing of the first
introduction to each country (Supplemental Fig. S1), we took the
date of the youngest node for any individual location in the pos-
terior distribution of trees.
Data access
The data have been deposited in the European Nucleotide Archive
(ENA) (http://www.ebi.ac.uk/ena/) under study numbers ERP000150
and ERP000633.
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